Dr Al Sanchez

SANCHEZ, Al
CANCER -- Treatment
VACCINES
AIDS (Disease) -- Treatment
DISTILLATION
Geographic Terms:
CALIFORNIA
THAILAND
UNITED States

Abstract:
Reports on the latest project of the Sanchez group led by Doctor Al Sanchez in California, as of March 2004. Details of the Poly-MVA cancer therapy introduced by Sanchez; Information on the oral therapeutic vaccine from Thailand, designed to cure AIDS; Role of the Sanchez group in developing techniques for atmospheric distillation.


POLY-MVA AS A REASON FOR HOPE
CANCER watch

USA -- The dramatic response of 5-year-old brain cancer patient Thomas Navarro to "alternative" therapies in which the experimental product Poly-MVA has played a key role has helped rivet attention on the latter.

While it is not clear that the manmade compound -- a non-toxic combination called Polydox for US trials and Poly-MVA for its increasing, ongoing use in Canada, Europe, the US and Mexico even though the countries have yet to officially legalize it -- alone caused the total disappearance of six recurrent medulloblastoma-associated tumors confirmed in February (see companion story) his parents believe it must have been a major contributor.

As such, it is adding to a long list of what the medical orthodoxy calls "anecdotes" -- hundreds of people from all walks of life have reported results ranging from simple pain relief to the dramatic disappearance of all cancer symptoms from using the liquid preparation.

Many "survivor" stories are available on the Web at www.polymvasurvivors.com, gathered by the US' primary information outlet on the subject:
AMARC (Advanced Medicine and Research Center) in Chula Vista CA.

AMARC Director Al Sanchez EdS PhD, a former Anaheim CA school principal turned cancer researcher after his first wife succumbed to the illness, makes no bones about it:

"If there is something better for cancer than Poly-MVA, I don't know what it is."

Sanchez' AMARC has distributed a number of non-toxic "alternative" products over the years, but he insists that the US-produced "Poly" is far and away the most promising compound he has dealt with.

It is legally available in the USA as a "super-nutrient" even though its supporters hope for eventual FDA approval of its medicinal uses, he said. It has been certified as a nutrient in Mexico, he added.

The brainchild of Dr. Merrill Garnett, a former dentist turned molecular biologist, Poly-MVA (the initials stand for "minerals, vitamins and amino acids") is produced at a New York laboratory whose principals are attempting to gather sufficient data to move the Garnett invention through the FDA's cumbersome and expensive licensing process.
Enthusiastic physicians (including the late Rudy Falk MD, an "alternative medicine" pioneer in Canada with a huge patient load) and patients themselves have praised the product, on which Dr. Garnett has secured patents, on a number of fronts:

It is cancer cell-specific -- that is, it does not affect normal tissue.

It is easy to take (ranging from a "tonic dose" of a half teaspoon a day mixed in water or juice to a "loading dose" of 2 tsp twice a day for 12 weeks.

It is non-toxic; that is, unlike standard chemotherapeutic agents it produces no negative side effects in the body.
It reduces the need for pain medication while lowering neurologically related distress and stimulating appetite.
From a biochemical standpoint, the product seems to involve the best of several worlds and has won the praise of such scientists as Dr. Paul M. Bingham, Department of Biochemistry and Cell Biology, State University of New York at Stony Brook, who notes that it "behaves as if it might be the hoped-for 'bullet' for cancer cell metabolism."
Variously defined as a palladium/lipoic acid complex and a polynucleotide reductase (i.e., an enzyme modifying the abnormal respiration found in cancer cells) Poly-MVA, also known to researchers as LAPd, is clearly specific against cancer cells without harming natural tissue.

However, it is its startling antioxidant properties (under the theory propounded by Dr. Garnett it actually converts toxic oxygen molecules -- reactive oxygen species [ROS, often if not always correctly called "free radicals"] -- into antioxidants) which help explain its useful activity ranging well beyond cancer.

Patients have spoken of relief from psoriasis, multiple sclerosis and Alzheimer's as well as dramatic effects from various "forms" of cancer -- including brain malignancy, since Poly-MVA demonstrably crosses the protective "blood-brain barrier."

Dr. Garnett's decades of study leading to the patented product in 1995 touches on several areas of investigation:
It exploits the Warburg "respiratory" hypothesis, is a strong nod to the oxidology approach to disease (the cancer-cell non-oxygen [anaerobic] condition as opposed to the oxygen-metabolizing nature of normal [aerobic] cells is of central importance), it relates to the "primordial cell theory" of cancer, it touches even on the old trophobiastic approach ("I see cancer as an embryo cell that can't make the next transition," Dr. Garnett has written), it relates to genetics and biological response modification and is heavily into electromagnetic medicine:

Indeed, the use of the metal palladium as a therapeutic met-allo-organic agent involved in cellular energy flow is the bedrock of the product.

On the downside, the ever-rising cost of the rare metal causes the product to be costly, although still competitive in comparison to the standard chemotherapy agents, radiation, experimental synthetic steroids and immunomodulatory proteins (and major oncological surgery) which make cancer treatment a hugely expensive component of the nation's trillion-dollar "healthcare delivery" bill.

The compound is often called a lipoic acid/palladium complex because of the lipoic acid -- also called alpha lipoic acid (ALA) -- content. In recent years, the utility of ALA on its own against various forms of metabolic disease has been on the rise.

As Al Sanchez has written:

"When lipoic acid, a powerful antioxidant with many biological functions, is connected with an electrically charged metal substrate (i.e., palladium), and joined with various B vitamins, the resulting complex becomes totally soluble in both water and fat.

"It can easily and safely travel throughout the body and into every cell."

The B vitamins associated with the ALA-palladium complex almost certainly play a role in the pain relief, appetite stimulation and several other effects of Poly-MVA use, doctors believe.

While some patients enthusiastically embrace the word "cure" when they speak of their Poly-MVA experience, doctors and researchers do not: the compound is extremely useful in cancer management and, if offered early in the diagnosis -- something rare in "alternative" circles -- may suppress symptoms long enough and fast enough to seem to be a cure, but evaluations of comparative 5-year survivals without symptoms are wanting.

Dr. Falk usually used Poly-MVA in combination with conventional cancer therapies. He, like others who have combined orthodox treatments with non-toxic "alternatives," usually found that the ancillary approaches seemed to make the standard ones "work better."

In many cases, such as those appearing on the Internet site and as is also the case with other non-toxic alternatives, Poly-MVA's role in advanced cancer has often been as a palliative -- it lengthens lives and reduces pain without overcoming the entire malignant process.

A February Internet posting by the survivors of Joyce Mat-son, for example, found that although the grade-three primary brain tumor patient died in June of last year she had been given at least six extra months of life, a point concurred in by amazed hospice nurses.

Far longer life extensions have occurred -- at least anecdotally -- in cases of brain, breast, prostate, colon, lung and stomach cancer.

Thanks to AMARC, the basic patent information and scientific articles on the development of Poly-MVA are available. And, thanks to the Website, those interested may find an abundance of anecdotal evidence attesting to the multiple virtues of the product.

Dr. Garnett has also written First Pulse (1998), his own explanation of his journey of discovery which led to "Poly."
Writing at times with the flair of a homeopath or, more likely, a mystic, Dr. Garnett observes:

"Ultimately there is a musical or harmonic element within the organism which can recreate the patterns of information and energy. This is beautiful and resurgent. This is molecular music, fragile, dependent, recurring under the right conditions, based in quantum echoes and hidden physics."

(Information on Poly-MVA, including the books of Drs. Garnett and Sanchez, is available from: AMARC, 539 Telegraph Canyon Rd., #281, Chula Vista CA 91910, tel. 619-656-1980, FAX 619-585-2980, E-mail: amarc@home.com, Web: www.polymvasurvivors.com.)
Just figure it out ...

UK, SPAIN-- Does one bad turn deserve another?

Possibly, if the issue is bladder cancer, according to a European study released last December.
Spain's Dr. Gonzalo Lopez Abente, of the Carlos III Health Institute, Madrid, and his team found that drinking coffee regularly might somehow protect cigarette smokers from bladder cancer.

In a survey of 497 people with bladder cancer and 1,100 without the disease, it was found that bladder cancer was about half as likely to occur in smokers who regularly drank coffee as in smokers who did not.

Experts not connected with the study published in the London-based Journal of Epidemiology and Community Health had mixed reactions to the findings -- ranging from the view that they highlighted often-unexpected protective benefits of substances found in food to the opinion that the study's methodology was flawed.
But all sides agreed that the best way to reduce the risk of bladder cancer is to stop smoking.

Share this with your friends
AttachmentSize
Dr Al Sanchez, Cancer Research.pdf382.57 KB